Future of HER2-Directed Tumor-Agnostic Therapies
Panelist discusses how HER2-directed tumor-agnostic treatments are likely to see expanded applications across multiple cancer types, driven by improved biomarker testing and emerging clinical evidence. This approach may become increasingly personalized through enhanced molecular profiling, potentially leading to more precise patient selection and combination strategies.
Video content above is prompted by the following:
- Where do you see the field of HER2-directed tumor-agnostic therapies evolving in the next 5 years?
Recent Videos
Related Content
Advancing Thoracic Surgery With Robotics and Video-Assisted Strategies
June 13th 2024Article
"Anything that you can do to leverage technology to minimize the variability in surgery eliminates the skill gap so that novice surgeons may become as technically gifted as the intermediate surgeon or the master surgeon."
